The findings, published in the journal Chronic Respiratory Disease, suggested that middle-aged testosterone replacement therapy users had a 4.2 per cent greater decrease in respiratory hospitalisations compared with non-users.
"We found that testosterone users had a greater decrease in respiratory hospitalisations compared with non-users," said co-author Jacques Baillargeon, Professor at the University of Texas Medical Branch in the US.
Low testosterone is common in men with COPD and may worsen their condition. Men with COPD have shortness of breath and often take steroid-based medications for an extended time, both of which increase their risk of low testosterone, the team said.
For the study, the researchers examined data of 450 men aged between 40 and 63 with COPD who began testosterone replacement therapy between 2005 and 2014.
The researchers also found that older testosterone replacement therapy users had a 9.1 per cent greater decrease in respiratory hospitalisations compared with non-users.
The aim of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalisations in middle-aged and older men with COPD, the team said.
"Previous studies have suggested that testosterone replacement therapy may have a positive effect on lung function in men with COPD. However, we are the first to conduct a large scale nationally representative study on this association," Baillargeon said.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)